Adherencia terapéutica del fentanilo transdérmico en pacientes con dolor oncológico en el servicio de Cuidados Paliativos del Instituto Oncológico Nacional SOLCA Guayaquil. Junio 2020 - junio 2021.

Abstract

For the treatment of moderate to severe cancer-related pain, opioids are the treatment of choice. Fentanyl is a synthetic opioid with a high affinity for the μ-opioid receptor and is 75-100 times more potent than morphine. OBJECTIVE: To determine adherence to analgesic treatment with transdermal fentanyl in the management of cancer pain. METHODOLOGY: Observational, descriptive, prospective and cross-sectional study. RESULTS: 104 patients were analyzed, 66.3% were female, mean age 59 years, 60.6% had a primary education level, according to the location of the tumor, the digestive system presented 38.5 %, 48.1% of the patients manifested mixed-type cancer pain, within the causes of non-adherence, demotivation was found with 2.9%, forgetfulness with 1% and stop going to the hospital with 1%, the Side effects were 12.5% constipation, 2.9% nausea, and 1% pruritus. The use of transdermal fentanyl began with EVA scale > 5, which was assessed in the follow-up consultations by adjusting the dose of transdermal fentanyl and even adding a rescue dose, until an adequate level of pain that was tolerable was achieved. CONCLUSIONS: In the study, most patients had good adherence to analgesic treatment with fentanyl in the management of cancer pain.